A detailed history of Israel Englander (Millennium Management LLC) transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 10,000 shares of VKTX stock, worth $525,900. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,000
Previous 11,600 13.79%
Holding current value
$525,900
Previous $614,000 3.09%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$49.84 - $70.47 $27.4 Million - $38.8 Million
-550,692 Reduced 76.17%
172,322 $10.9 Million
Q2 2024

Aug 14, 2024

BUY
$47.39 - $80.2 $15.4 Million - $26.1 Million
325,925 Added 82.08%
723,014 $38.3 Million
Q1 2024

May 15, 2024

SELL
$17.4 - $94.5 $100,345 - $544,981
-5,767 Reduced 1.43%
397,089 $32.6 Million
Q4 2023

Feb 14, 2024

SELL
$9.24 - $19.64 $13.1 Million - $27.9 Million
-1,420,264 Reduced 77.9%
402,856 $7.5 Million
Q2 2023

Aug 14, 2023

SELL
$14.84 - $24.79 $29.9 Million - $49.9 Million
-2,014,876 Reduced 52.5%
1,823,120 $29.6 Million
Q1 2023

May 15, 2023

SELL
$8.08 - $17.33 $4.4 Million - $9.44 Million
-544,504 Reduced 12.42%
3,837,996 $63.9 Million
Q4 2022

Feb 14, 2023

BUY
$2.72 - $9.4 $3.48 Million - $12 Million
1,279,469 Added 41.23%
4,382,500 $41.2 Million
Q3 2022

Nov 14, 2022

BUY
$2.55 - $3.89 $4.56 Million - $6.96 Million
1,788,275 Added 136.02%
3,103,031 $8.44 Million
Q2 2022

Aug 15, 2022

SELL
$2.11 - $3.15 $394,844 - $589,459
-187,130 Reduced 12.46%
1,314,756 $3.8 Million
Q1 2022

May 16, 2022

BUY
$3.0 - $4.88 $3.89 Million - $6.33 Million
1,296,236 Added 630.31%
1,501,886 $4.51 Million
Q4 2021

Feb 14, 2022

BUY
$4.6 - $6.72 $673,633 - $984,090
146,442 Added 247.33%
205,650 $946,000
Q3 2021

Nov 15, 2021

BUY
$5.58 - $7.04 $64,348 - $81,185
11,532 Added 24.19%
59,208 $372,000
Q2 2021

Aug 16, 2021

BUY
$5.19 - $6.73 $247,438 - $320,859
47,676 New
47,676 $286,000
Q4 2020

Feb 16, 2021

SELL
$5.3 - $6.71 $185,982 - $235,460
-35,091 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$5.73 - $8.11 $2.09 Million - $2.97 Million
-365,603 Reduced 91.24%
35,091 $204,000
Q2 2020

Aug 14, 2020

BUY
$4.35 - $8.08 $1.54 Million - $2.86 Million
353,447 Added 748.08%
400,694 $2.89 Million
Q1 2020

May 14, 2020

BUY
$3.45 - $7.95 $163,002 - $375,613
47,247 New
47,247 $221,000
Q4 2019

Feb 14, 2020

SELL
$6.38 - $8.73 $1.08 Million - $1.48 Million
-169,070 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$6.55 - $8.6 $1.11 Million - $1.45 Million
169,070 New
169,070 $1.16 Million
Q1 2019

May 14, 2019

SELL
$7.58 - $9.94 $628,382 - $824,026
-82,900 Closed
0 $0
Q4 2018

Feb 14, 2019

SELL
$7.16 - $16.21 $2.05 Million - $4.64 Million
-286,516 Reduced 77.56%
82,900 $634,000
Q3 2018

Nov 14, 2018

SELL
$9.7 - $19.65 $3.6 Million - $7.29 Million
-371,188 Reduced 50.12%
369,416 $6.44 Million
Q2 2018

Aug 14, 2018

SELL
$3.88 - $12.74 $2.56 Million - $8.39 Million
-658,766 Reduced 47.08%
740,604 $7.03 Million
Q1 2018

May 15, 2018

BUY
$4.11 - $6.93 $2.86 Million - $4.83 Million
696,398 Added 99.06%
1,399,370 $6.12 Million
Q4 2017

Feb 14, 2018

BUY
$1.74 - $4.34 $1.22 Million - $3.05 Million
702,972
702,972 $2.85 Million

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track Israel Englander's Portfolio

Track Israel Englander Portfolio

Follow Israel Englander (Millennium Management LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.